OCUL

Ocular Therapeutix Inc

May 18 • 04:00PM ET

8.38

-0.78 -8.52 %

Healthcare • Biotechnology • USA • Small • NASD

| Held by: VTI IWM VXF IWO PJP VTWO SCHA XPH DFAS VHT

Index	RUT	P/E	-	EPS (ttm)	-1.46	Insider Own	9.58%	Shs Outstand	218.90M	Perf Week	-9.70%
Market Cap	1.83B	Forward P/E	-	EPS next Y	-1.45	Insider Trans	-0.78%	Shs Float	197.99M	Perf Month	-14.66%
Enterprise Value	1.25B	PEG	-	EPS next Q	-0.38	Inst Own	89.23%	Short Float	12.52%	Perf Quarter	19.89%
Income	-290.50M	P/S	35.26	EPS this Y	-9.45%	Inst Trans	3.97%	Short Ratio	4.73	Perf Half Y	-25.11%
Sales	52.04M	P/B	3.15	EPS next Y	6.92%	ROA	-51.03%	Short Interest	24.79M	Perf YTD	-30.97%
Book/sh	2.66	P/C	2.75	EPS next 5Y	2.78%	ROE	-68.55%	52W High	16.44 -49.03%	Perf Year	16.07%
Cash/sh	3.04	P/FCF	-	EPS past 3/5Y	-15.40% 11.13%	ROIC	-44.16%	52W Low	6.23 34.51%	Perf 3Y	31.55%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	0.29% 24.45%	Gross Margin	87.24%	Volatility	5.64% 4.79%	Perf 5Y	-40.10%
Dividend TTM	-	EV/Sales	23.97	EPS Y/Y TTM	-26.75%	Oper. Margin	-575.42%	ATR (14)	0.50	Perf 10Y	-27.57%
Dividend Ex-Date	-	Quick Ratio	14.73	Sales Y/Y TTM	-12.76%	Profit Margin	-558.24%	RSI (14)	36.71	Recom	1.08
Dividend Gr. 3/5Y	- -	Current Ratio	14.81	EPS Q/Q	-4.58%	SMA20	-10.92%	Beta	0.91	Target Price	26.17
Payout	-	Debt/Eq	0.14	Sales Q/Q	0.81%	SMA50	-6.44%	Rel Volume	0.57	Prev Close	9.16
Employees	325	LT Debt/Eq	0.13	Earnings	May 05 BMO	SMA200	-23.24%	Avg Volume	5.24M	Price	8.38
IPO	Jul 25, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-27.06% -15.23%	Trades		Volume	2,983,887	Change	-8.52%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-15-25	Initiated	Chardan Capital Markets	Buy	$21
Apr-08-25	Initiated	William Blair	Outperform
Mar-18-25	Initiated	RBC Capital Mkts	Outperform	$17
Mar-11-25	Initiated	Needham	Buy	$15
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jun-20-24	Upgrade	TD Cowen	Hold → Buy	$7 → $11
May-31-24	Resumed	Piper Sandler	Overweight	$15
Feb-09-24	Initiated	BofA Securities	Buy	$15
Apr-21-23	Initiated	Robert W. Baird	Outperform	$18
Aug-10-22	Resumed	Berenberg	Buy	$15
Aug-10-21	Upgrade	H.C. Wainwright	Neutral → Buy	$17
Dec-28-20	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-17-20	Initiated	Berenberg	Buy	$27
Nov-13-20	Reiterated	Raymond James	Strong Buy	$15 → $25
Aug-10-20	Reiterated	H.C. Wainwright	Buy	$10 → $13
Mar-03-20	Upgrade	Raymond James	Outperform → Strong Buy
May-21-19	Reiterated	H.C. Wainwright	Buy	$12 → $9
May-21-19	Downgrade	Raymond James	Strong Buy → Outperform	$11 → $5
May-21-19	Downgrade	Cowen	Outperform → Market Perform	$13 → $3
Dec-03-18	Reiterated	Cantor Fitzgerald	Overweight	$22 → $24

Show Previous Ratings

May-15-26 07:00AM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-08-26 04:05PM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-05-26 07:31AM	Ocular Therapeutix: Q1 Earnings Snapshot (Associated Press)
07:00AM	Ocular Therapeutix Reports First Quarter 2026 Financial Results and Business Highlights (GlobeNewswire)
Apr-29-26 07:00AM	Ocular Therapeutix Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI in Wet AMD (GlobeNewswire)
07:00AM	Loading…
Apr-28-26 07:00AM	Ocular Therapeutix to Report First Quarter 2026 Financial Results on May 5, 2026 (GlobeNewswire)
Apr-27-26 07:00AM	Ocular Therapeutix to Participate in May Scientific and Investor Conferences (GlobeNewswire)
Apr-22-26 07:00AM	Ocular Therapeutix to Host Investor Day on June 17, 2026 (GlobeNewswire)
Apr-14-26 07:00AM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-13-26 07:00AM	Ocular Therapeutix Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD (GlobeNewswire)
Apr-01-26 07:00AM	Ocular Therapeutix to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April (GlobeNewswire)
Mar-20-26 06:12PM	EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug (Reuters)
Mar-09-26 04:01PM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-28-26 09:31AM	Ocular Therapeutix, Inc. (OCUL): A Bull Case Theory (Insider Monkey)
Feb-27-26 04:35PM	Ocular Therapeutix (OCUL) Stock Trades Down, Here Is Why (StockStory) -6.78% +22.82%
07:00AM	Loading…
Feb-24-26 07:00AM	Ocular Therapeutix to Participate in March Investor Conferences (GlobeNewswire) +6.48%
03:12AM	Ocular Therapeutix Shares Jump After AXPAXLI Hits SOL-1 Phase 3 Endpoint in Wet AMD (MarketBeat)
Feb-23-26 07:00AM	Ocular Therapeutix to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations (GlobeNewswire) +8.10%
Feb-19-26 06:01PM	Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes (Benzinga) +10.67%
10:41AM	Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses (Newsfile)
Feb-17-26 04:59PM	Ocular Therapeutix Shares Jump 28% as SOL-1 Nears Key Data (GuruFocus.com) -21.28%
09:15AM	Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes (Benzinga)
08:30AM	Ocular Therapeutix stock news: Why positive data led to a 25% drop (Investing.com)
07:00AM	Ocular Therapeutix Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD (GlobeNewswire)
06:07AM	Ocular claims a win with Phase 3 eye drug data even as shares sink (BioPharma Dive)
06:07AM	Ocular claims a win with eye drug data even as shares sink (BioPharma Dive)
05:26AM	Stock Market Today: Dow Futures Gain, Nasdaq Drags-ZIM Integrated Shipping, Masimo, Toll Brothers In Focus (Benzinga)
Feb-13-26 05:00PM	Ocular Therapeutix to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026 (GlobeNewswire)
Feb-06-26 04:01PM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-05-26 04:06PM	Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates (StockStory)
08:10AM	Loading…
08:10AM	Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:12AM	Ocular Therapeutix: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Ocular Therapeutix Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights (GlobeNewswire)
Jan-26-26 10:34PM	A Look Back at Pharmaceuticals Stocks' Q3 Earnings: Ocular Therapeutix (NASDAQ:OCUL) Vs The Rest Of The Pack (StockStory) +6.04%
Jan-23-26 04:01PM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.64%
Jan-21-26 07:00AM	Ocular Therapeutix Appoints David W. Robinson as Global Chief Commercial Officer (GlobeNewswire)
Jan-15-26 04:25PM	Stocks to Watch Thursday: Penumbra, BlackRock, Goldman Sachs (The Wall Street Journal)
04:20PM	Ocular Launches, And Then Yo-Yoes, On Rumors Sanofi Is Preparing A Bigger Bid (Investor's Business Daily)
01:03PM	Ocular Therapeutix, Inc. (OCUL): A Bull Case Theory (Insider Monkey)
10:30AM	Ocular Therapeutix Shares Surge Following Reports Of Stronger Sanofi Bid (Benzinga)
09:47AM	Ocular Therapeutix Launches On Rumors Sanofi Is Preparing A Bigger Bid (Investor's Business Daily)
09:37AM	Stocks to Watch Thursday: Goldman Sachs, Boston Scientific, BlackRock (The Wall Street Journal)
09:26AM	Strength Seen in Ocular Therapeutix (OCUL): Can Its 6.1% Jump Turn into More Strength? (Zacks)
Jan-13-26 11:04PM	3 Reasons OCUL is Risky and 1 Stock to Buy Instead (StockStory) +6.14%
Jan-02-26 06:07PM	Ocular Therapeutix (NASDAQ:OCUL) Surprises With Q3 CY2025 Sales (StockStory)
Dec-31-25 11:25AM	BofA Bullish on Ocular Therapeutix (OCUL) as AXPAXLI Targets Superiority Label and Faster Regulatory Path in Wet AMD (Insider Monkey)
Dec-11-25 07:44AM	H.C. Wainwright Lifts Ocular Therapeutix, Inc. (OCUL) Price Target Following Intravitreal Implant FDA Submission (Insider Monkey)
Dec-09-25 02:23PM	Ocular Therapeutix (OCUL) Hits 4-Year High on Axpaxli NDA Application (Insider Monkey)
Dec-08-25 07:00AM	Ocular Therapeutix Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI in Wet AMD (GlobeNewswire) +28.06%
Dec-05-25 07:00AM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-24-25 07:00AM	Ocular Therapeutix Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI in NPDR (GlobeNewswire)
Nov-20-25 09:55AM	Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 82.48%: Read This Before Placing a Bet (Zacks)
Nov-18-25 12:44AM	Ocular Therapeutix (OCUL) Soars 5% Ahead of Health Conferences (Insider Monkey)
Nov-12-25 01:37PM	Ocular Therapeutix Stock Earns 81 RS Rating (Investor's Business Daily)
07:00AM	Ocular Therapeutix to Participate in November and December Investor Conferences (GlobeNewswire)
Nov-10-25 08:16PM	RBC Capital Raises PT on Ocular Therapeutix (OCUL) to $24 Amid Solid Growth Trajectory (Insider Monkey)
Nov-07-25 07:00AM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-04-25 04:02PM	Ocular Therapeutix Inc (OCUL) Q3 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
08:45AM	Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:43AM	Ocular Therapeutix: Q3 Earnings Snapshot (Associated Press Finance)
07:05AM	Ocular Therapeutix Reports Third Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
07:00AM	Ocular Therapeutix Achieves Target Randomization of 555 Subjects in SOL-R (GlobeNewswire)
Nov-03-25 07:33AM	Ocular Therapeutix Inc (OCUL) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-30-25 09:55AM	Wall Street Analysts Believe Ocular Therapeutix (OCUL) Could Rally 82.93%: Here's is How to Trade (Zacks)
Oct-28-25 07:00AM	Ocular Therapeutix to Report Third Quarter 2025 Financial Results on November 4, 2025 (GlobeNewswire)
Oct-24-25 09:55AM	Ocular Therapeutix (OCUL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Oct-17-25 09:54PM	H.C. Wainwright Lifts PT on Ocular Therapeutix (OCUL) to $19 From $15, Keeps a Buy Rating (Insider Monkey)
Oct-08-25 12:57AM	Piper Sandler Lifts PT on Ocular Therapeutix (OCUL) to $31 From $21 (Insider Monkey)
Oct-07-25 07:00AM	Ocular Therapeutix to Participate in Upcoming Scientific Conferences (GlobeNewswire) +5.01%
Oct-02-25 12:46AM	Ocular Therapeutix (OCUL) Falls Hard on $475-Million Share Sale (Insider Monkey)
Sep-30-25 07:08AM	Ocular Therapeutix Announces Pricing of Underwritten Offering of Common Stock (GlobeNewswire) -6.70%
06:21AM	Ocular Therapeutix Investor Day to Highlight Exceptional AXPAXLI Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint (GlobeNewswire)
Sep-24-25 04:06AM	Chardan Capital Initiates Ocular Therapeutix (OCUL) With a Buy Rating (Insider Monkey)
Sep-08-25 07:00AM	Ocular Therapeutix to Host Investor Day on September 30, 2025 (GlobeNewswire) -6.54%
Aug-27-25 07:00AM	Ocular Therapeutix to Participate in September Investor and Scientific Conferences (GlobeNewswire)
Aug-12-25 07:00AM	Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial of AXPAXLI in NPDR (GlobeNewswire)
Aug-05-25 08:25AM	Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:25AM	Ocular Therapeutix: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Ocular Therapeutix Reports Second Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Aug-04-25 09:37AM	Ocular Therapeutix Inc (OCUL) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Jul-29-25 07:00AM	Ocular Therapeutix to Report Second Quarter 2025 Financial Results on August 5, 2025 (GlobeNewswire)
Jul-22-25 07:00AM	Ocular Therapeutix to Participate in Upcoming Scientific Conferences (GlobeNewswire)
Jun-26-25 01:54PM	Ocular Therapeutix Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company (GlobeNewswire)
Jun-25-25 11:13AM	Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last? (Zacks)
Jun-16-25 07:00AM	Ocular Therapeutix to Participate in Clinical Trials at the Summit (CTS) 2025 (GlobeNewswire)
May-28-25 07:00AM	Ocular Therapeutix To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI in Wet Age-Related Macular Degeneration (GlobeNewswire) +13.69%
May-14-25 07:00AM	Ocular Therapeutix to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-05-25 08:15AM	Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -12.16%
07:11AM	Ocular Therapeutix: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Ocular Therapeutix Reports First Quarter 2025 Results and Business Highlights (GlobeNewswire)
May-02-25 09:25AM	Ocular Therapeutix Inc (OCUL) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Apr-29-25 10:01AM	Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for (Zacks)
07:00AM	Ocular Therapeutix to Participate in Upcoming Investor and Scientific Conferences (GlobeNewswire)
Apr-28-25 07:00AM	Ocular Therapeutix to Report First Quarter 2025 Financial Results on May 5, 2025 (GlobeNewswire) +5.45%
Apr-11-25 04:30PM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +11.01% +6.47%
Mar-31-25 07:00AM	Ocular Therapeutix to Participate in Two Investor Conferences in April (GlobeNewswire)
Mar-14-25 08:36AM	Why Ocular Therapeutix Was Bumping Higher This Week (Motley Fool)
Mar-11-25 02:49PM	Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside (Benzinga) +11.24%
Mar-07-25 04:05PM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-04-25 02:00AM	Ocular Therapeutix Inc (OCUL) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com) +9.70%

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Executive ChairmanDr. Pravin U. Dugel M.D.

CFOMr. Donald Notman Jr.

Chief Commercial OfficerMr. Steve Meyers

Ph.D.Mr. Sanjay Nayak MBBS

M.P.H.Dr. Nadia K. Waheed M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dugel Pravin	See Remarks	Feb 23 '26	Sale	8.28	20,056	166,064	3,013,022	Feb 25 06:20 PM
Kaiser Peter	Chief Development Officer	Feb 23 '26	Sale	8.28	2,810	23,267	269,108	Feb 25 06:19 PM
Heier Jeffrey S.	Chief Scientific Officer	Feb 23 '26	Sale	8.28	3,057	25,312	323,368	Feb 25 06:18 PM
Nayak Sanjay	Chief Strategy Officer	Feb 23 '26	Sale	8.28	1,759	14,565	330,653	Feb 25 06:17 PM
Waheed Nadia	Chief Medical Officer	Feb 20 '26	Sale	7.74	3,510	27,167	314,907	Feb 24 06:13 PM
LINDSTROM RICHARD L MD	Director	Feb 20 '26	Buy	7.66	60,229	461,354	246,933	Feb 24 06:13 PM
PETER KAZUO KAISER	Officer	Feb 23 '26	Proposed Sale	8.28	2,810	23,268		Feb 23 04:23 PM
PRAVIN DUGEL	Officer	Feb 23 '26	Proposed Sale	8.28	20,056	166,086		Feb 23 04:21 PM
JEFFREY S. HEIER	Officer	Feb 23 '26	Proposed Sale	8.28	3,057	25,298		Feb 23 04:18 PM
SANJAY NAYAK	Officer	Feb 23 '26	Proposed Sale	8.28	1,759	14,563		Feb 23 04:16 PM
NADIA K. WAHEED	Officer	Feb 20 '26	Proposed Sale	7.74	3,510	27,170		Feb 20 04:36 PM
Notman Donald	Chief Operating Officer	Feb 12 '26	Sale	9.04	11,446	103,472	366,356	Feb 17 08:31 PM
Nayak Sanjay	Chief Strategy Officer	Feb 12 '26	Sale	9.04	10,348	93,546	332,412	Feb 17 08:30 PM
Dugel Pravin	See Remarks	Feb 12 '26	Sale	9.04	124,882	1,128,933	3,033,078	Feb 17 08:29 PM
Waheed Nadia	Chief Medical Officer	Feb 12 '26	Sale	9.04	7,863	71,082	318,417	Feb 17 08:28 PM
DONALD D NOTMAN JR.	Officer	Feb 12 '26	Proposed Sale	9.04	11,446	103,481		Feb 12 04:33 PM
PRAVIN DUGEL	Officer	Feb 12 '26	Proposed Sale	9.04	124,882	1,128,584		Feb 12 04:20 PM
STEVE MEYERS	Officer	Feb 12 '26	Proposed Sale	9.04	6,864	62,034		Feb 12 04:18 PM
SANJAY NAYAK	Officer	Feb 12 '26	Proposed Sale	9.04	10,348	93,560		Feb 12 04:16 PM
NADIA K. WAHEED	Officer	Feb 12 '26	Proposed Sale	9.04	7,863	71,082		Feb 12 04:09 PM
Notman Donald	Chief Operating Officer	Feb 04 '26	Sale	8.54	6,035	51,539	377,802	Feb 04 08:23 PM
Notman Donald	Chief Operating Officer	Feb 02 '26	Sale	9.14	5,455	49,859	383,837	Feb 04 08:23 PM
STEVE MEYERS	Officer	Feb 04 '26	Proposed Sale	8.54	4,408	37,636		Feb 04 04:10 PM
DONALD D NOTMAN JR.	Officer	Feb 04 '26	Proposed Sale	8.54	6,035	51,541		Feb 04 04:09 PM
DONALD D NOTMAN JR.	Officer	Feb 02 '26	Proposed Sale	9.14	5,455	49,873		Feb 02 04:29 PM
STEVE MEYERS	Officer	Feb 02 '26	Proposed Sale	9.14	3,052	27,904		Feb 02 04:28 PM
Nayak Sanjay	Chief Strategy Officer	Nov 24 '25	Sale	12.04	1,878	22,611	277,860	Nov 26 04:02 PM
Dugel Pravin	See Remarks	Nov 24 '25	Sale	12.04	19,530	235,141	3,157,960	Nov 26 04:02 PM
Kaiser Peter	Chief Development Officer	Nov 24 '25	Sale	12.02	3,007	36,144	191,433	Nov 26 04:01 PM
Heier Jeffrey S.	Chief Scientific Officer	Nov 24 '25	Sale	12.04	3,469	41,767	245,940	Nov 26 04:01 PM
PRAVIN DUGEL	Officer	Nov 24 '25	Proposed Sale	12.04	19,530	235,083		Nov 24 04:33 PM
SANJAY NAYAK	Officer	Nov 24 '25	Proposed Sale	12.04	1,878	22,616		Nov 24 04:31 PM
PETER KAZUO KAISER	Officer	Nov 24 '25	Proposed Sale	12.02	3,007	36,150		Nov 24 04:30 PM
JEFFREY S. HEIER	Officer	Nov 24 '25	Proposed Sale	12.04	3,469	41,772		Nov 24 04:28 PM
Saroj Namrata	Chief Business Officer	Nov 05 '25	Sale	10.74	25,865	277,790	174,135	Nov 07 04:01 PM
NAMRATA SAROJ	Officer	Nov 05 '25	Proposed Sale	10.74	25,865	277,909		Nov 05 04:20 PM
Anderman Todd	Chief Legal Officer	Oct 08 '25	Sale	12.34	11,132	137,369	87,568	Oct 10 04:01 PM
TODD ANDERMAN	Officer	Oct 08 '25	Proposed Sale	12.34	11,132	137,400		Oct 08 04:03 PM
Kaiser Peter	Chief Development Officer	Oct 02 '25	Sale	11.03	9,653	106,473	194,440	Oct 06 05:13 PM
Heier Jeffrey S.	Chief Scientific Officer	Oct 02 '25	Sale	11.04	10,502	115,942	249,409	Oct 06 05:10 PM
JEFFREY S. HEIER	Officer	Oct 02 '25	Proposed Sale	11.04	10,502	115,890		Oct 02 04:11 PM
PETER KAZUO KAISER	Officer	Oct 02 '25	Proposed Sale	11.03	9,653	106,516		Oct 02 04:08 PM
Notman Donald	See Remarks	Sep 02 '25	Sale	12.43	1,066	13,250	308,807	Sep 04 04:50 PM
DONALD D NOTMAN JR.	Officer	Sep 02 '25	Proposed Sale	12.43	1,066	13,245		Sep 02 04:10 PM
Kaiser Peter	Chief Development Officer	Aug 25 '25	Sale	12.04	3,011	36,252	204,093	Aug 27 06:44 PM
Nayak Sanjay	Chief Strategy Officer	Aug 25 '25	Sale	12.04	1,885	22,695	279,738	Aug 27 06:43 PM
Heier Jeffrey S.	Chief Scientific Officer	Aug 25 '25	Sale	12.04	3,063	36,879	259,911	Aug 27 06:42 PM
Dugel Pravin	See Remarks	Aug 25 '25	Sale	12.04	21,494	258,788	3,227,244	Aug 27 06:41 PM
PRAVIN DUGEL	Officer	Aug 25 '25	Proposed Sale	12.04	21,494	258,758		Aug 25 04:19 PM
SANJAY NAYAK	Officer	Aug 25 '25	Proposed Sale	12.04	1,885	22,702		Aug 25 04:18 PM
JEFFREY S. HEIER	Officer	Aug 25 '25	Proposed Sale	12.04	3,063	36,883		Aug 25 04:17 PM
PETER KAZUO KAISER	Officer	Aug 25 '25	Proposed Sale	12.04	3,011	36,253		Aug 25 04:16 PM
Waheed Nadia	Chief Medical Officer	Jun 02 '25	Sale	8.05	13,861	111,581	206,805	Jun 03 04:20 PM
NADIA K. WAHEED	Officer	Jun 02 '25	Proposed Sale	8.05	13,861	111,524		Jun 02 04:40 PM
Nayak Sanjay	Chief Strategy Officer	May 23 '25	Sale	7.17	1,862	13,351	281,623	May 27 05:42 PM
Kaiser Peter	Chief Development Officer	May 23 '25	Sale	7.17	2,974	21,324	207,104	May 27 05:40 PM
Heier Jeffrey S.	Chief Scientific Officer	May 23 '25	Sale	7.18	3,024	21,712	262,974	May 27 05:39 PM
Dugel Pravin	See Remarks	May 23 '25	Sale	7.18	21,219	152,352	3,499,099	May 27 05:37 PM
PETER KAZUO KAISER	Officer	May 23 '25	Proposed Sale	7.17	2,974	21,323		May 23 04:14 PM
JEFFREY S. HEIER	Officer	May 23 '25	Proposed Sale	7.18	3,024	21,707		May 23 04:11 PM
PRAVIN DUGEL	Officer	May 23 '25	Proposed Sale	7.18	21,219	152,289		May 23 04:08 PM
SANJAY NAYAK	Officer	May 23 '25	Proposed Sale	7.17	1,862	13,347		May 23 04:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OCUL

Ocular Therapeutix Inc

Upgrade your Finviz experience